Investor Communication

In 1992, CMS was established in Shenzhen.

On 28 September 2010, CMS was listed on the Main Board of the Stock Exchange of Hong Kong Ltd. (stock code: 867)

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicating to providing competitive products and services to fulfill the unmet clinical needs.

CMS focuses on developing first- or best-in-class innovative products and has deployed 30 differentiated pipeline products with relatively high level of innovation and great market potential. CMS deeply engages in specialty therapeutic fields. It has developed proven commercialization capabilities, extensive network and expert resources, and won leading academic and market positions for its major marketed products. With deeply rooted in the specialty areas while expanding its business boundaries, it continued to strengthen the competitiveness of its cardio-cerebrovascular/ gastroenterology business, and independently operated dermatology and medical aesthetic business, and ophthalmology business to enhance the scale and efficiency of operation; Meanwhile, it entered into the Southeast Asian market to create new driving force, further escorting the sustainable and healthy development of the Group.

As of 31 December 2022, CMS has 5,647 employees, including over 4,300 professional academic promotional staff.

31 December each year.

Annual results announcement will be published no later than three months after the end of related financial year; interim results announcement will be published no later than two months after the end of first half of the financial year.

Deloitte Touche Tohmatsu is the auditor of CMS.

The electronic financial reports and announcements can be viewed and downloaded from the official website of SEHK (www.hkex.com.hk) or “Investor Relations” column of CMS’s official website.